![]() ![]() Lead times for deals: “We have really seen much longer time needed to close rounds. There’s some correction there but maybe not to the same extent.” Earlier valuations pre-seed and seed are somewhat less impacted. So later stage valuations… we are talking Series B, C, and growth stage definitely went down. ![]() Valuations: “Valuations have come down, but it very much depends on the stage. So I think, overall, this trend is healthy.” So we see a healthy correction in fact, where investors are looking for companies with stronger fundamentals. I think it’s fair to say there was some initial hype in this industry, and this is now subsiding. “But I think a few other things changed as well. If you look at the percentage year-over-year drop, it’s roughly in line, maybe a little bit more than what we see overall in the VC market. So I think the main driver of the drop of investment in alt protein is actually coming from the overall VC market correction. Funding: “Obviously the macro situation changed over that period (2021-2023). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |